Please stay tuned for important disclosure information at the conclusion of this episode.

Here's what's ahead on this week's Investing Insights, why investors should consider higher bond yields

and interest rates the norm, and not anomalies, plus Morning Stars outlooks for Apple and Eli Lilly

and the sales of their popular products and a look at the

debate where the companies with union workers can compete against firms that are non-union.

This is Investing Insights.

Welcome to Investing Insights. I'm your host, Ivana Hampton. Let's get started with a look at the Morning Star headlines. Apple reported a solid fiscal fourth quarter. Revenue came in a bit under $90 billion. It dipped year over year, but fell in line with Morning Star's expectations. iPhone sales were up, and it's a good sign that demand for iPhone 15s

will continue, although the macroeconomic environment remains shaky. Gross margin reached a record high

of about 45% thanks to cheaper components. Those usually refer to memory chips. Switching to in-house processors within iPhones,

iPads, and Macs also contributed. Services revenue impressed as more subscribers join Apple's iOS

ecosystem, and that provides opportunities to upsell apps and services. Morningstar predicts Apple's revenue

will be flattish for the December quarter. iPad and wearables revenue should be down significantly

due to the timing of new product launches compared with last year. Morningstar estimates Apple's

stock is worth $150 and modestly overvalued.

Diabetes drug Moundaro and other medications help lift Eli Lilly's third quarter results.

Sales rose 24% even after excluding coronavirus products and the sale of one of the company's drug portfolios.

Morningstar expects this rate to continue over the next couple of years.

Moundjaro brought in $1.4 billion in sales and remains key to Eli Lilly's growth potential,

and it could reach annual sales of over $30 billion.

Lilly has also made strides and increasing its supply of Mount Jaro so that it will no longer appear on the FDA's drug shortage list.

However, Morning Star thinks supply constraints may limit the medication internationally in 2024.

Lilly's remaining portfolio and pipeline are performing well.

...